Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) version of Entyvio, its treatment for adults with moderate to severe Crohn’s disease (CD).
Global biopharmaceutical company Takeda is working to modernize its operations in order to better serve clinical trial sites, patients and sponsor outcomes.
The Biotechnology Innovation Organization elected the fresh slate of leaders during the BIO International Convention, taking place in San Diego this week.
A probe has identified 'human error’ at the Spanish contract development and manufacturing organization, Rovi, as the reason for the presence of metal contaminants in Moderna COVID-19 vaccine doses, leading to Japanese authorities withdrawing 1.6...
Takeda has received approval from Japan’s ministry of health to manufacture and market its stem cell therapy, Alofisel, for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease (CD).
Japan’s health ministry is to secure 150 million doses of Novavax’ vaccine candidate that Takeda is producing. The Japanese government's purchasing agreement is subject to regulatory approvals.
After Finch Therapeutics extends partnership with Takeda, the biotech’s CEO outlines how next year could be a defining one for microbiome-based therapies.
The news most interesting to our readers were those featuring collaborations, whether in the production of an Ebola vaccine, biosimilars entering new markets or creating new manufacturing modalities.
Noile-Immune signs its second high profile agreement, the latest with Adaptimmune to combine the companies’ technology in pre-clinical studies for the treatment of cancer.
Amgen and Takeda will join fellow big pharma companies Sanofi, GSK, and Janssen, in working to progress Feldan’s intracellular drug delivery technology.
The market for cell therapy products is set to expand based on increasing investment from the industry and the implementation of advanced manufacturing technologies.
